Proteomics Tools Market Forecast to Grow at ~4% p.a., Reaching ~$39B by 2030 – Market Report by DeciBio Consulting LLC

Audio By Carbonatix

LOS ANGELES--(BUSINESS WIRE)--Oct 28, 2025--

DeciBio Consulting LLC, a leading market intelligence and strategy consulting firm, announced the publication of its first edition, “Proteomics Tools Report: Research and Clinical markets (2025-2030).” This comprehensive report forecasts the global proteomics tools market to reach approximately $39 billion by 2030, growing at a compound annual growth rate (CAGR) of ~4% from an estimated $32 billion in 2025.

DeciBio’s Proteomics Tools Market Report offers an in-depth analysis of the proteomics tools landscape. Informed by a combination of primary research with key stakeholders (including 20 in-depth interviews and 50 surveys), extensive secondary research, and proprietary DeciBio databases and tools, this report provides both a quantitative and qualitative assessment of the key market segments and trends.

The proteomics tools market is both a foundational component of the life sciences industry and an area experiencing a resurgence in innovation. Given that proteins represent the functional endpoints of biological pathways, their analysis is fundamental to understanding disease pathobiology, making proteomics a critical area for research and clinical investment. The market is defined by a clear duality: established, first-generation tools such as IHC, ELISAs, and Western blots remain indispensable workhorses in clinical trials and routine diagnostics, anchoring a large, stable segment of the market. In parallel, the rapid adoption of innovative technologies, including high-plex affinity platforms and spatial proteomics, which enable deep multiomic insights, drives growth across research segments.

This report covers proteomics tools from discovery research to routine clinical diagnostics, providing a detailed analysis of these critical market segments. A diverse group of companies service this ecosystem, from large corporations competing broadly across antibodies, reagents, and instrumentation to niche players focused on disruptive next-generation platforms.

Report Details:

• Research Methods:
  • Secondary research: analysis of SEC filings, conference abstracts, publications, clinical trials, earnings call transcripts, and company websites
  • Primary research: 20 interviews and 50 surveys with stakeholders from universities, biopharma, CROs, and hospitals across the world
  • Proprietary databases & analysis: use of internal databases and tools (e.g., Dexter expert network, other DeciBio market reports, e.g., In-Vitro Diagnostics (coming soon), Pharma R&D Services)
• 2030 Market Size: ~$39 billion
• CAGR (2025-2030): ~4%
• Base Year: 2025
• Forecast Period: 2025-2030
• Market / Forecast Currency: USD
• Report Coverage:
  • Market size, segmentation, and forecast
  • Key market players and trends
  • Services and technologies
  • Market drivers and moderators
  • Publication and clinical trial analysis
  • Competitive analysis

Segments Covered:

• Technology/Tool Type: Standard Immunoassays (ELISA, Western Blot), Mass Spectrometry, Capillary Electrophoresis, Protein Microarrays, High Plex Affinity Assays, Protein Sequencing, Conventional IHC/IF, Spatial & Imaging Proteomics
• Product Type: Instruments, Reagents
• Customer: Academia, Biopharma, CRO, Clinical
• Application/Use Case: Basic / Functional Research & Discovery, Preclinical Research, Translational / Clinical Research, Routine Clinical (Diagnostics)
• Product Designation: Research Use Only (RUO), In-Vitro Diagnostic (IVD)
• Plex Level: 1-2 Plex, 3-19 Plex, 20-99 Plex, 100+ Plex
• Geography: United States, Europe, Asia Pacific (APAC), Rest of World (ROW)

Proteomics Tool Providers Profiled:

• End-to-End & Mass Spectrometry Leaders: Thermo Fisher Scientific (including Olink), Bruker (including Nanostring), Sciex, Waters
• High-Plex & Spatial Innovators: Illumina (including SomaLogic), Quanterix (including Akoya Biosciences)
• Clinical & Pathology Leaders: Roche, Agilent, Leica Biosystems
• Reagent & Immunoassay Specialists: Abcam, Bio-Rad
• Emerging Technology: Quantum-Si

Market Drivers:

The report identifies several key factors that will drive the growth of the proteomics tools market. A primary driver is the direct relevance of proteins to disease biology, providing a functional readout of cellular states. This makes proteomics a high-priority area for research and clinical investment, from biomarker discovery to companion diagnostics. The rapid evolution of emerging technologies is also a major catalyst. Next-generation protein sequencing is enabling de novo discovery and deep characterization of post-translational modifications, while spatial proteomics is seeing rapid adoption for its ability to resolve cellular interactions within the tumor microenvironment. Furthermore, the increasing emphasis on multiomics integration is a powerful tailwind, as combining proteomics with genomics and transcriptomics provides a more holistic, systems-level understanding of disease. An expanding clinical utility and increasing need for precision medicine are also fueling growth, as protein-based biomarkers become essential for patient stratification, diagnostics and the development of companion diagnostics for targeted therapies.

Market Moderators:

The report also discusses several moderating factors. The complexity of high-dimensional data remains a significant barrier, as the analysis of datasets from high-plex and spatial platforms requires specialized bioinformatics expertise and robust computational infrastructure, which can restrict broader adoption. Persistent funding pressures, particularly in academic settings, can delay capital expenditure on high-cost instrumentation, leading labs to rely on older, established technologies or outsource to core facilities and CROs. Significant regulatory hurdles constrain the clinical adoption of novel platforms, as the pathway from a Research Use Only tool to a validated in-vitro diagnostic is long and costly. Moreover, workflow and standardization challenges, such as sample preparation variability and a lack of cross-platform data harmonization, can impact reproducibility and slow the broad adoption of newer technologies.

Overall, the growth drivers are expected to outweigh the moderators during the 5-year forecast window. Miguel Edwards, Ph.D., Partner at DeciBio Consulting, says, "Proteomics is gaining momentum as advances in mass spectrometry, affinity-based platforms, and single-molecule detection unlock new levels of sensitivity and scale. It is adapting to meet a growing demand from biopharma and diagnostics for dynamic, functional insights that go beyond genomics and transcriptomics."

For more information on DeciBio’s Proteomics Tools Market Report (2025-2030), please contact [email protected].

About DeciBio:

DeciBio Consulting ( www.decibio.com ) is a leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, with additional offices in the Bay Area, New York City, and London, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251028062588/en/

CONTACT: Hannah Glazier

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: CONSULTING BIOTECHNOLOGY PROFESSIONAL SERVICES HEALTH GENERAL HEALTH HEALTH TECHNOLOGY OTHER SCIENCE RESEARCH DATA ANALYTICS SCIENCE CLINICAL TRIALS

SOURCE: DeciBio Consulting LLC

Copyright Business Wire 2025.

PUB: 10/28/2025 08:16 AM/DISC: 10/28/2025 08:16 AM

http://www.businesswire.com/news/home/20251028062588/en